| Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water S Man, G Bocci, G Francia, SK Green, S Jothy, D Hanahan, P Bohlen, ... Cancer Research 62 (10), 2731-2735, 2002 | 426 | 2002 |
| Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts G Klement, P Huang, B Mayer, SK Green, S Man, P Bohlen, D Hicklin, ... Clinical cancer research 8 (1), 221-232, 2002 | 368 | 2002 |
| Research ethics recommendations for whole-genome research: consensus statement T Caulfield, AL McGuire, M Cho, JA Buchanan, MM Burgess, U Danilczyk, ... PLoS biology 6 (3), e73, 2008 | 302 | 2008 |
| Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies G Bocci, S Man, SK Green, G Francia, JML Ebos, JM Du Manoir, ... Cancer research 64 (18), 6616-6625, 2004 | 215 | 2004 |
| Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro SK Green, G Francia, C Isidoro, RS Kerbel Molecular cancer therapeutics 3 (2), 149-159, 2004 | 136 | 2004 |
| Adhesion-dependent multicellular drug resistance SK Green, A Frankel, RS Kerbel Anti-cancer drug design 14 (2), 153-168, 1999 | 121 | 1999 |
| Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer SK Green, MCI Karlsson, JV Ravetch, RS Kerbel Cancer research 62 (23), 6891-6900, 2002 | 94 | 2002 |
| Placebo use in vaccine trials: recommendations of a WHO expert panel A Rid, A Saxena, AH Baqui, A Bhan, J Bines, MC Bouesseau, A Caplan, ... Vaccine 32 (37), 4708-4712, 2014 | 69 | 2014 |
| Placebo use in vaccine trials: recommendations of a WHO expert panel A Rid, A Saxena, AH Baqui, A Bhan, J Bines, MC Bouesseau, A Caplan, ... Vaccine 32 (37), 4708-4712, 2014 | 69 | 2014 |
| Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents G Francia, SK Green, G Bocci, S Man, U Emmenegger, JML Ebos, ... Molecular cancer therapeutics 4 (10), 1484-1494, 2005 | 46 | 2005 |
| Guidelines to prevent malevolent use of biomedical research SK Green, S Taub, K Morin, D Higginson Cambridge Quarterly of Healthcare Ethics 15 (4), 432-439, 2006 | 29 | 2006 |
| Addressing ethical, social, and cultural issues in global health research JV Lavery, SK Green, SVS Bandewar, A Bhan, A Daar, CI Emerson, ... PLoS neglected tropical diseases 7 (8), e2227, 2013 | 27 | 2013 |
| Balancing safety, efficacy and cost: Improving rotavirus vaccine adoption in low-and middle-income countries A Bhan, SK Green Journal of Global Health 1 (2), 148, 2011 | 13 | 2011 |
| Probability of HIV transmission among injecting drug users in Glasgow D Goldberg, M Frischer, ST Green, A Taylor, N McKeganey Unpublished manuscript, 1995 | 10 | 1995 |
| Chapter 6: physician professionalism and preparing for epidemics: challenges and opportunities MK Wynia, JF Kurlander, SK Green Ethics and Epidemics, 135-161, 2006 | 7 | 2006 |
| How many drug injectors are there in the UK? M Frischer, D Goldberg, S Green | 7 | 1993 |
| E3LSI Research: An Essential Element of Biodefense SK Green Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 3 …, 2005 | 6 | 2005 |
| Physician-Scientists and Social Responsibility SK Green AMA Journal of Ethics 6 (9), 416-419, 2004 | 5 | 2004 |
| Collaborative development of expertise: Evaluation of an on-the-job (OJT) training program T Stanard, RM Pliske, AA Armstrong, S Green, CE Zsambok, ... Proceedings of the Human Factors and Ergonomics Society Annual Meeting 46 …, 2002 | 5 | 2002 |
| Biodefense: spend, but spend wisely SK Green, K Morin The American Journal of Bioethics 5 (4), 50-52, 2005 | 3 | 2005 |
